How Morphine Metabolism Works in the Human Body

Morphine is broken down almost entirely in the liver, where enzymes attach sugar molecules to it in a process called glucuronidation. This produces two main metabolites that have very different effects: one is inactive and even counterproductive, while the other is a painkiller in its own right. How your body handles these metabolites, how quickly it clears them, and how much morphine reaches your brain in the first place all shape what you actually feel after a dose. The story is more intricate than most people realize, because the “waste products” of morphine turn out to be pharmacologically important players on their own.

Why So Little Morphine Survives the Trip From Your Gut

When you swallow a morphine tablet, a large fraction of the drug never makes it into general circulation. It gets absorbed from the intestine and goes straight to the liver via the portal vein, where enzymes immediately begin converting it into metabolites before it can reach the rest of the body. This “first-pass” effect is substantial. In healthy volunteers given oral morphine solution, absolute bioavailability was estimated at roughly 24%.¹ A study in cancer patients found a similar figure of about 37%, with the first-pass process converting about 36% of the oral dose to the inactive metabolite M3G and about 6% to the active metabolite M6G before morphine even enters systemic blood.²

Bioavailability also depends on who is taking the drug. In people who have used opioids chronically, oral morphine bioavailability can climb to around 37%, while in opioid-naive individuals the figure sits closer to 24%.³ The practical upshot is that oral morphine dosing has to be significantly higher than intravenous dosing to produce the same blood levels, and the exact ratio varies from person to person.

The Two Metabolites That Matter Most

Once morphine reaches the liver, the dominant metabolic pathway is glucuronidation, in which a family of enzymes called UDP-glucuronosyltransferases (UGTs) attach a glucuronic acid group to the morphine molecule. Depending on where that group attaches, the result is one of two metabolites: morphine-3-glucuronide (M3G) or morphine-6-glucuronide (M6G). M3G is produced in far greater quantities; it accounts for roughly 60% of a morphine dose’s metabolic output, while M6G accounts for roughly 10%. Multiple UGT enzymes can produce M3G, but only one, UGT2B7, is responsible for forming M6G.⁴ That single enzyme effectively controls how much of the painkilling metabolite you produce.

M3G does not bind opioid receptors in any meaningful way and provides zero pain relief. Worse, research in animals has shown that M3G can actually increase pain sensitivity. Rats injected with M3G developed heightened touch sensitivity, an effect that depended on a specific immune-signaling pathway involving Toll-like receptor 4.⁵ Separate work in mice confirmed that M3G-induced pain amplification required the presence of functional mu-opioid receptors, adding further complexity to the picture.⁶ For patients, this raises a genuine clinical question: when morphine seems to stop working or even make pain worse, part of the explanation could be the buildup of M3G.

M6G, by contrast, is a potent painkiller. When injected directly into the brain of rats, M6G was 60 to 200 times more potent than morphine itself, depending on the pain test used.⁷ In humans, M6G appears to produce analgesia comparable to morphine but with a more favorable side-effect profile, meaning less nausea, vomiting, and respiratory depression.⁸ Both morphine and M6G work through the mu-opioid receptor, but M6G has slightly higher efficacy at that receptor even though morphine has slightly higher binding affinity. M6G also has less activity at kappa-opioid receptors, which may help explain why it produces fewer unpleasant side effects.

A Minor Pathway That Shows Up in Drug Testing

Glucuronidation is not the only thing the liver does with morphine. A small fraction undergoes a reaction called N-demethylation, which strips off a methyl group and produces a metabolite called normorphine. This pathway is handled primarily by two cytochrome P450 enzymes, CYP3A4 and CYP2C8, which together account for more than 90% of normorphine formation.⁹ Normorphine itself has limited clinical significance for pain relief, but it can show up in urine drug screens and has some relevance in forensic toxicology.

Another minor metabolite is hydromorphone, which can form in trace amounts during morphine metabolism. This is occasionally relevant in hair or urine testing, where its presence alongside morphine can help analysts distinguish a single exposure from chronic use.¹⁰ The point is that although glucuronidation dominates, these side pathways produce metabolites that matter for drug monitoring even if they do not contribute much to pain control.

Getting Into the Brain

Pain relief only happens once morphine or its active metabolite M6G reaches the central nervous system. Both molecules have to cross the blood-brain barrier, and the barrier does not make this easy. P-glycoprotein, a transport pump embedded in the barrier’s lining, actively pushes certain molecules, including morphine, back out of the brain. Research in a rat model demonstrated that blocking P-glycoprotein increased morphine uptake into brain tissue, confirming that the pump limits how much drug gets through.¹¹ In humans, a study using the immunosuppressant cyclosporine, which inhibits this efflux pump, found measurable increases in morphine’s effects on the brain, indicating that P-glycoprotein genuinely constrains how much morphine accesses its site of action.¹²

Whether common P-glycoprotein inhibitors taken alongside morphine in everyday clinical settings actually change brain exposure enough to matter is less clear. A modeling study simulated the impact of several known P-glycoprotein inhibitors and concluded that the effect on morphine concentrations in brain fluid was negligible for most of the simulated population.¹³ So while the pump clearly plays a role, typical drug combinations are unlikely to blow the gate wide open.

M6G faces an even harder time crossing the barrier than morphine does, because attaching a glucuronic acid group makes the molecule more water-soluble and less able to slip through fatty cell membranes. M6G does eventually reach the brain, but slowly, which contributes to its delayed onset and prolonged duration of action compared to morphine.

How Morphine Leaves the Body

The kidneys are the primary exit route for morphine’s metabolites. Both M3G and M6G are water-soluble glucuronides that get filtered into urine. In patients with normal kidney function, the renal clearance of these metabolites tracks closely with overall kidney filtration rate.¹⁴ Morphine itself is also partly cleared by the kidneys, but interestingly, its unbound renal clearance actually exceeds the glomerular filtration rate, suggesting active secretion into the urine on top of passive filtering.

There is also a secondary elimination loop involving the gut. After the liver converts morphine to glucuronides, a portion is excreted into bile and dumped into the small intestine. Gut bacteria can then strip off the glucuronic acid group, regenerating free morphine, which gets reabsorbed through the intestinal wall and cycled back to the liver. This enterohepatic recirculation extends morphine’s time in the body and contributes to the prolonged tail of its elimination curve.¹⁵ In rats, pretreating with antibiotics to knock out intestinal bacteria dramatically reduced this recycling, cutting the amount of recirculated morphine from about 41% of the infused dose down to roughly 9%.¹⁶ This has practical implications: anything that disrupts gut bacteria, including antibiotics, could theoretically change how long morphine lingers in the system.

Kidney Failure Changes Everything

Because the kidneys are the main exit route for M3G and M6G, kidney failure causes these metabolites to pile up in the blood. In patients on peritoneal dialysis, the ratio of M6G to morphine in the blood was about 13.5 times higher than in patients with healthy kidneys, and the M3G-to-morphine ratio was about 5.5 times higher.¹⁷ Dialysis was almost useless for clearing these molecules, with clearance rates of only about 3 milliliters per minute.

This metabolite accumulation has real clinical consequences. A series of case reports described patients with kidney impairment who developed classic signs of opioid toxicity, including severe respiratory depression, even though morphine itself had already been cleared from their blood. The culprit was accumulated M6G, which persists far longer than morphine when the kidneys cannot flush it.¹⁸ This finding was confirmed in a separate study showing that kidney transplantation reversed the metabolite accumulation, providing direct proof that the kidney is the key clearing organ for glucuronide metabolites.¹⁹ For anyone with significant kidney disease, morphine is either used at sharply reduced doses or avoided altogether in favor of opioids that do not produce active glucuronide metabolites.

Liver Disease and Morphine

Because the liver is where glucuronidation happens, you might expect liver disease to impair morphine metabolism. It does, though perhaps less dramatically than you would guess. Glucuronidation is generally more resilient to liver damage than the oxidative reactions handled by cytochrome P450 enzymes, but severe cirrhosis still disrupts it. In patients with advanced cirrhosis, morphine clearance was significantly reduced and its oral bioavailability was substantially higher than normal, meaning more of each oral dose survives to enter the bloodstream.²⁰

In practical terms, the elimination half-life of controlled-release morphine in cirrhotic patients was nearly twice that of healthy controls, roughly 7.4 hours versus 4 hours, and peak blood concentrations were about three times higher.²¹ Patients with cirrhosis also experienced more sedation. The clinical guidance is straightforward: lower doses and longer intervals between doses for anyone with significant liver impairment.

Why Newborns Handle Morphine Differently

Morphine metabolism changes dramatically over the first years of life. Newborns, especially premature infants, have very low levels of the UGT2B7 enzyme responsible for producing M6G, and their overall glucuronidation capacity is limited. The ratio of M3G to morphine in infants is roughly 7.3, compared to about 23.9 in older children, reflecting their immature metabolic machinery.²² Morphine clearance increases with age as both UGT2B7 expression and liver blood flow increase, with the transition being especially rapid during the first few months of life.²³ This is why neonatal morphine dosing is extremely conservative and requires close monitoring: the drug is cleared much more slowly, and the risk of accumulation is much higher.

Genetic Variation in Morphine Metabolism

Given that UGT2B7 is the gatekeeper for M6G production, it seems logical that genetic variants in this enzyme would explain why some people respond brilliantly to morphine while others get little relief. The reality is frustratingly murky. Among cancer patients on chronic morphine, the plasma ratios of M3G-to-morphine and M6G-to-morphine varied enormously between individuals, with M6G-to-morphine ratios differing 42-fold across the patient group. Yet when researchers looked at the most commonly studied UGT2B7 variant (H268Y), they found no statistically significant difference in metabolite ratios between genotypes.²⁴

Laboratory studies with recombinant enzymes tell a more complex story. Certain UGT2B7 variants do alter the relative production of M3G versus M6G, and when these enzymes pair up with variants of UGT1A1 or UGT1A9 in functional dimers, the balance can shift further toward M6G production.²⁵ The disconnect between test-tube findings and patient outcomes suggests that real-world morphine metabolism is shaped by so many factors simultaneously, including kidney function, liver blood flow, concurrent medications, and gut microbiome composition, that any single gene variant gets drowned out in the noise.

Genetics may matter more for morphine transport than for morphine metabolism per se. A variant in the ABCB1 gene, which encodes P-glycoprotein, significantly predicted how well patients responded to a combination of morphine and the antidepressant nortriptyline for neuropathic pain. People with two copies of the C allele at the rs1045642 position showed an 88% improvement in pain scores, compared to only 20% for those with two copies of the T allele.²⁶ However, a separate study found that ABCB1 variants did not significantly alter the ratio of morphine in cerebrospinal fluid versus blood, complicating the picture of exactly where and how the transporter gene variant is acting.²⁷ The field is still sorting out which genetic tests, if any, could reliably predict morphine response.

Drug Interactions That Affect Morphine Metabolism

Because morphine is processed mainly by glucuronidation rather than the cytochrome P450 system, it avoids the vast web of drug interactions that plagues medications cleared by CYP enzymes. But glucuronidation is not immune to interference. Cannabis is increasingly used alongside opioids for pain, and laboratory studies show that THC and CBD both inhibit UGT2B7-mediated morphine metabolism. Static modeling predicted that inhaled cannabis containing THC, or oral cannabis products containing both THC and CBD, could produce a clinically meaningful drug interaction with morphine.²⁸ Whether this translates to real-world toxicity in patients using both agents has not been definitively established in clinical trials, but it is a plausible concern.

NSAIDs, which are routinely combined with morphine for multimodal pain management, have also been tested for their ability to inhibit morphine glucuronidation. Most common NSAIDs turned out to be weak inhibitors. Mefenamic acid was the notable exception, with modeling predicting a roughly 40% increase in morphine blood levels when the two drugs are co-administered. Diclofenac and naproxen, by contrast, were predicted to raise morphine levels by less than 10 to 15%, an amount unlikely to matter in practice.²⁹ For the typical patient taking ibuprofen or naproxen with morphine, this particular interaction is not a clinical worry.

When Morphine Is Delivered Straight to the Spinal Cord

Oral and intravenous morphine both rely on systemic circulation, meaning the drug has to travel through the bloodstream, cross the blood-brain barrier, and reach opioid receptors in the brain and spinal cord. Intrathecal delivery, in which morphine is injected directly into the cerebrospinal fluid surrounding the spinal cord, bypasses most of these steps. Because morphine is relatively water-soluble compared to more lipophilic opioids, it tends to stay in the cerebrospinal fluid longer, spreading widely along the spinal cord and providing prolonged analgesia at very low doses.³⁰ Both morphine and its glucuronide metabolites are detectable in the cerebrospinal fluid and plasma of patients receiving chronic intrathecal infusion, confirming that local metabolism still occurs even with spinal delivery.³¹

The flip side of morphine’s hydrophilicity in this context is that some drug does eventually get absorbed into systemic circulation, and it also has a tendency to spread rostrally (upward) in the cerebrospinal fluid toward the brainstem, which is why delayed respiratory depression is a recognized risk of intrathecal morphine even hours after the injection. This long dwell time is both the drug’s advantage and its hazard when delivered spinally.

Your Body Actually Makes Its Own Morphine

One of the more surprising findings in opioid biology is that human cells can synthesize morphine from scratch, using dopamine as a starting material. Researchers demonstrated this by growing human neuroblastoma cells in an environment containing a heavy-oxygen isotope; the morphine the cells produced incorporated that isotope, proving it was made internally rather than absorbed from outside contamination.³² The biosynthetic pathway follows the same sequence of chemical intermediates found in poppy plants, passing through compounds like reticuline and thebaine on the way to morphine. Endogenous morphine has since been found in various mammalian tissues and is now recognized as structurally identical to the plant-derived alkaloid.³³

The amounts produced are tiny, in the low-nanomolar range, and it remains unclear what physiological role endogenous morphine plays. It could be involved in pain modulation, stress responses, or immune regulation, but the research is still in early stages. What it does mean practically is that extremely sensitive forensic assays can occasionally detect trace morphine in people who have not taken any opioid, a detail that has created headaches in drug-testing interpretation.